Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Annmarie Stephenson Thomas

Gastroenterology Rockville, MD Doctor of Osteopathy

NPI 1376742601 CMS profile 108169

9420 Key West Avenue, Suite 202, Rockville, MD 20850

Open in the dashboard

General payments

$3,319

181 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Annmarie Stephenson Thomas of Rockville, MD is reported in the CMS Open Payments database as having received $3,319 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $757 34
2024 General $1,002 57
2023 General $888 50
2022 General $69 4
2021 General $24 1
2020 General $103 1
2019 General $475 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Annmarie Stephenson Thomas
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Annmarie Stephenson Thomas were reported at $757. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Annmarie Stephenson Thomas Gastroenterology median Middle half National median
2019 $475 $417 $126–$1,100 $163
2020 $103 $224 $74–$624 $114
2021 $24 $352 $106–$1,054 $132
2022 $69 $448 $129–$1,270 $149
2023 $888 $533 $150–$1,390 $160
2024 $1,002 $605 $160–$1,606 $164
2025 $757 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $509 30 payments
  2. AbbVie, Inc. $464 17 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $388 31 payments
  4. Celgene Corporation $372 25 payments
  5. Regeneron Healthcare Solutions, Inc. $326 18 payments
  6. Ardelyx, Inc. $182 6 payments
  7. Intercept Pharmaceuticals, Inc. $144 6 payments
  8. Genzyme Corporation $144 6 payments
  9. Janssen Biotech, Inc. $135 7 payments
  10. QOL Medical, LLC $106 6 payments
  11. Other $548 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,285 177 payments
  2. Education $34 4 payments
Products named General payments · program years 2019–2025
  1. ENTYVIO $400 22 payments
  2. ZEPOSIA $372 25 payments
  3. XIFAXAN $263 20 payments
  4. HUMIRA $255 5 payments
  5. DUPIXENT Inflammation And Immunology $241 14 payments
  6. IBSRELA $182 6 payments
  7. TRULANCE $168 11 payments
  8. DUPIXENT Immunology $144 6 payments
  9. CREON $123 8 payments
  10. OCALIVA $118 5 payments
  11. Other $1,450 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

347

Median for Gastroenterology: 569

Drug cost

$53,171

Median for Gastroenterology: $104,976

Branded share of claims

33.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 19 $31,949
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 42 $7,096
Dexlansoprazole Dr Dexlansoprazole Brand 13 $5,186
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 41 $2,624
Omeprazole Generic 98 $1,963
Famotidine Generic 94 $1,876
Colestipol Hcl Generic 12 $1,718
Sucralfate Generic 14 $584
Pantoprazole Sodium Generic 14 $176

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$60,917

Medicare's payments for the services billed

Medicare patients

275

Average age 73

Services billed

804

215 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 53%
Diabetes 27%
Osteoporosis 26%
Depression 21%
Ischemic heart disease 19%
Chronic kidney disease 18%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $139
  • GENZYME CORPORATION $40
$179 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $126
$126 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $108
$108 — —
ZEPOSIA
  • Celgene Corporation $91
$91 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record